Dear , 

PhoreMost has developed a next-generation phenotypic screening platform called 'Site-Seeker' to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited. 

Next-Generation Screening Platform 

There has been considerable progress in identifying hundreds of underlying genetic causes in cancer and other human diseases over the last 10-years. However, most of these new candidate drug targets are not impacted by current drug discovery technologies, and they are seen as “undruggable”.

Opportunity

PhoreMost has developed a screening platform called ‘SiteSeeker’, which can identify cryptic druggable sites on these targets, and ways in which they can be rapidly drugged with novel small-molecule therapies. Aligned with this technology is a wide experience in developing and screening live cells to identify and validate key disease targets and novel candidate therapeutics to them. In this way, PhoreMost will be uniquely placed to deliver a pipeline of highly selective and patient-specific drugs for cancer and other conditions currently lacking therapeutic options. The company will also develop ways in which to apply such treatments cost-effectively.

The Team

Chris Torrance, co-founder and CEO, was a founder of Horizon Discovery (LSE: HZD), which completed its IPO in March 2014, raising £37.8 million.

Ashok Venkitaraman, co-founder and CSO, is the Ursula Zoellner Professor of Cancer Research at the University of Cambridge and Director of the Medical Research Council (MRC) Cancer Unit and well-known for his work on breast cancer. Much of the work to validate PhoreMost’s approach in discovering the chemical probes to validate targets has been carried out in Professor Venkitaraman’s laboratory in Cambridge.

Hermann Hauser, who joins PhoreMost’s Board of Directors, says: “Pinpointing the causes of disease will enable us to pinpoint therapies and PhoreMost’s work is at the forefront of protein analysis and modulation. We are delighted to be able to support such a distinguished team in developing this important platform.”

This financial promotion is issued by Parkwalk Advisors Limited (Parkwalk), which is authorised and regulated by the Financial Conduct Authority.  Investments referred to in this newsletter are not suitable for all investors.  Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any Parkwalk product.  Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change. Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Parkwalk is not able to provide advice as to the suitability of investing in a Parkwalk product.